CN109071588A - 尿苷类磷酰胺前药、其制备方法及其在医药上的应用 - Google Patents

尿苷类磷酰胺前药、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN109071588A
CN109071588A CN201780018366.3A CN201780018366A CN109071588A CN 109071588 A CN109071588 A CN 109071588A CN 201780018366 A CN201780018366 A CN 201780018366A CN 109071588 A CN109071588 A CN 109071588A
Authority
CN
China
Prior art keywords
compound
prodrug
group
substituted
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780018366.3A
Other languages
English (en)
Other versions
CN109071588B (zh
Inventor
王国成
吴会敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Original Assignee
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Tasly Diyi Pharmaceutical Co Ltd filed Critical Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Publication of CN109071588A publication Critical patent/CN109071588A/zh
Application granted granted Critical
Publication of CN109071588B publication Critical patent/CN109071588B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

本发明涉及一种尿苷类磷酰胺前药、其制备方法及其在医药上的应用，本发明所述的前药是如通式Ⅰ所示的化合物或其光学异构体或其药学上可接受的盐，本发明所述的前药还包括，如通式Ⅰ所示的化合物或其光学异构体或其药学上可接受的盐的溶剂化物，本发明所述的前药可以治疗病毒感染性疾病，特别是丙肝病毒感染性疾病。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201780018366.3A 2016-03-25 2017-03-22 尿苷类磷酰胺前药、其制备方法及其在医药上的应用 Active CN109071588B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610180475 2016-03-25
CN2016101804752 2016-03-25
PCT/CN2017/077693 WO2017162169A1 (zh) 2016-03-25 2017-03-22 尿苷类磷酰胺前药、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN109071588A true CN109071588A (zh) 2018-12-21
CN109071588B CN109071588B (zh) 2021-07-06

Family

ID=59899318

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710173179.4A Withdrawn CN107226831A (zh) 2016-03-25 2017-03-22 尿苷类磷酰胺前药、其制备方法及其在医药上的应用
CN201780018366.3A Active CN109071588B (zh) 2016-03-25 2017-03-22 尿苷类磷酰胺前药、其制备方法及其在医药上的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710173179.4A Withdrawn CN107226831A (zh) 2016-03-25 2017-03-22 尿苷类磷酰胺前药、其制备方法及其在医药上的应用

Country Status (12)

Country Link
US (1) US10745434B2 (zh)
EP (1) EP3434685B1 (zh)
JP (1) JP6890132B2 (zh)
KR (1) KR20180122333A (zh)
CN (2) CN107226831A (zh)
AU (1) AU2017239338B2 (zh)
CA (1) CA3010462A1 (zh)
HK (1) HK1258984A1 (zh)
IL (1) IL261193B (zh)
RU (1) RU2740760C2 (zh)
TW (1) TW201733596A (zh)
WO (1) WO2017162169A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105983016B (zh) 2015-03-23 2023-08-11 天士力医药集团股份有限公司 一种含有水飞蓟宾的药物组合
CN114262348A (zh) * 2020-09-16 2022-04-01 上海本仁科技有限公司 环状核苷磷酸酯类化合物及其应用
CN113234102A (zh) * 2021-05-18 2021-08-10 宁波大学 一种三配位磷衍生物及中间体及制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121634A2 (en) * 2007-03-30 2008-10-09 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2012142075A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN103224530A (zh) * 2012-08-13 2013-07-31 洛阳聚慧投资股份有限公司 一组替诺福韦酯化合物、制备方法及其在抗病毒方面的应用
CN103435672A (zh) * 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
WO2013187978A1 (en) * 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN103980332A (zh) * 2013-12-09 2014-08-13 南京迈勒克生物技术研究中心 2′-氟-2′-(氟甲基)-2′-脱氧核苷类化合物及其磷酸酯潜药
CN105307661A (zh) * 2013-05-16 2016-02-03 里博科学有限责任公司 4’-叠氮基,3’-脱氧基-3’-氟取代的核苷衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2466729C2 (ru) * 2006-12-28 2012-11-20 Айденикс Фармасьютикалз, Инк. Соединения и фармацевтические композиции для лечения вирусных инфекций
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121634A2 (en) * 2007-03-30 2008-10-09 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2012142075A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013187978A1 (en) * 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN104640444A (zh) * 2012-06-16 2015-05-20 南京迈勒克生物技术研究中心 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药
CN103224530A (zh) * 2012-08-13 2013-07-31 洛阳聚慧投资股份有限公司 一组替诺福韦酯化合物、制备方法及其在抗病毒方面的应用
CN103435672A (zh) * 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
CN105307661A (zh) * 2013-05-16 2016-02-03 里博科学有限责任公司 4’-叠氮基,3’-脱氧基-3’-氟取代的核苷衍生物
CN103980332A (zh) * 2013-12-09 2014-08-13 南京迈勒克生物技术研究中心 2′-氟-2′-(氟甲基)-2′-脱氧核苷类化合物及其磷酸酯潜药

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UGO PRADERE，等: "Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs", 《CHEMICAL REVIEWS》 *

Also Published As

Publication number Publication date
CN107226831A (zh) 2017-10-03
EP3434685B1 (en) 2021-06-16
RU2018125748A3 (zh) 2020-04-23
TW201733596A (zh) 2017-10-01
RU2018125748A (ru) 2020-01-13
EP3434685A1 (en) 2019-01-30
HK1258984A1 (zh) 2019-11-22
IL261193A (en) 2018-10-31
EP3434685A4 (en) 2019-11-13
US10745434B2 (en) 2020-08-18
CA3010462A1 (en) 2017-09-28
KR20180122333A (ko) 2018-11-12
CN109071588B (zh) 2021-07-06
AU2017239338B2 (en) 2020-08-27
AU2017239338A1 (en) 2018-07-19
US20180371004A1 (en) 2018-12-27
JP2019514843A (ja) 2019-06-06
RU2740760C2 (ru) 2021-01-20
WO2017162169A1 (zh) 2017-09-28
JP6890132B2 (ja) 2021-06-18
IL261193B (en) 2020-10-29

Similar Documents

Publication Publication Date Title
EP3305795B1 (en) Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof
TWI498117B (zh) 核苷氨基磷酸酯
BR112015003778B1 (pt) Profármaco de tenofovir, composição farmacêutica, e seus usos
CN104292256A (zh) N-[ (2`r)-2`-脱氧-2`-氟-2`-甲基-p-苯基-5`-尿苷酰基]-l-丙氨酸1-甲基乙基酯及其制备方法
CN109071588B (zh) 尿苷类磷酰胺前药、其制备方法及其在医药上的应用
TW201605885A (zh) 尿嘧啶核苷酸類似物及其製備方法和應用
ES2639863A1 (es) Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato
CN105085383A (zh) 5-甲基-2(1h)吡啶酮衍生物及其制备方法和用途
CN114524716B (zh) β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用
CN111655710B (zh) 吉西他滨含磷前药
WO2020151296A1 (zh) 双核苷酸前体药物及其制备方法
CN111285900B (zh) 基于紫檀芪和香荚兰乙酮的偶联分子dcz0847类化合物、其制备方法及用途
CN110590838A (zh) Y27632前药、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1258984

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant